TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD

Cells. 2023 Jan 17;12(3):341. doi: 10.3390/cells12030341.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology worldwide. In mice and humans, NAFLD progression is characterized by the appearance of TREM2-expressing macrophages in the liver. However, their mechanistic contributions to disease progression have not been completely elucidated. Here, we show that TREM2+ macrophages prevent the generation of a pro-inflammatory response elicited by LPS-laden lipoproteins in vitro. Further, Trem2 expression regulates bone-marrow-derived macrophages (BMDMs) and Kupffer cell capacity to phagocyte apoptotic cells in vitro, which is dependent on CD14 activation. In line with this, loss of Trem2 resulted in an increased pro-inflammatory response, which ultimately aggravated liver fibrosis in murine models of NAFLD. Similarly, in a human NAFLD cohort, plasma levels of TREM2 were increased and hepatic TREM2 expression was correlated with higher levels of liver triglycerides and the acquisition of a fibrotic gene signature. Altogether, our results suggest that TREM2+ macrophages have a protective function during the progression of NAFLD, as they are involved in the processing of pro-inflammatory lipoproteins and phagocytosis of apoptotic cells and, thereby, are critical contributors for the re-establishment of liver homeostasis.

Keywords: TREM2; fibrosis; inflammation; lipoproteins; macrophages; metabolic-associated fatty liver disease (MAFLD); nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); phagocytosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Humans
  • Liver Cirrhosis / pathology
  • Macrophages / metabolism
  • Membrane Glycoproteins / genetics
  • Mice
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Receptors, Immunologic

Substances

  • TREM2 protein, human
  • Membrane Glycoproteins
  • Receptors, Immunologic
  • Trem2 protein, mouse

Grants and funding

This research was funded by the DFG (450149205-TRR333/1 to L.S. (P13), J.H. (P05), L.B. (P07) and A.W. (P07)) and (SFB 841 to J.H.(B06) and L.B. (P02)). In addition, L.S., J.H., L.B. and A.W. were supported by the State of Hamburg (LFF-FV75). A.W. was supported by the Mühlbauer-fundation.